Do Traders Think Curis, Inc. (CRIS) Can Turn Around Monday?

The market has been high on Curis, Inc. (CRIS) stock recently. CRIS gets a Bullish score from InvestorsObserver Stock Sentiment Indicator.

Curis, Inc. has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on CRIS!

See Full CRIS Report

What is Stock Sentiment?

Sentiment is a very short-term indicator that is entirely technical. There is no information about the health of profitability of the underlying company in our sentiment score. As a technical indicator, news about the stock, or company, such as an earnings release or other event, could move the stock counter to the recent trend. Changes in price are generally the best indicator of sentiment for a particular stock. At its core, a stock's trend indicates whether current market sentiment is bullish or bearish. Investors must be bullish if a stock is trending upward, and are bearish if a stock is moving down. InvestorsObserver's Sentiment Indicator factors in both price changes and variations in volume. An increase in volume usually means a current trend is stengthening, while a drop in volume tends to signal a reversal to the ongoing trend. Our system also uses the options market in order to receive additional signals on current sentiments. We take into account the ratio of calls and puts for a stock since options allow an investor to bet on future changes in price.

What's Happening With CRIS Stock Today?

Curis, Inc. (CRIS) stock has fallen -8.13% while the S&P 500 is higher by 0.46% as of 1:16 PM on Monday, Dec 12. CRIS is lower by -$0.06 from the previous closing price of $0.77 on volume of 5,808,419 shares. Over the past year the S&P 500 is down -15.34% while CRIS is lower by -84.70%. CRIS lost -$0.64 per share in the over the last 12 months. To see InvestorsObserver's Sentiment Score for Curis, Inc. click here.

More About Curis, Inc.

Curis Inc is a biotechnology company that develops and commercializes innovative drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, advanced solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge. Click Here to get the full Stock Report for Curis, Inc. stock.